|
WO2020102261A1
|
|
Methods and systems for somatic mutations and uses thereof
|
|
CA3075265A1
|
|
Method of using biomarkers and clinical variables for predicting chemotherapy benefit
|
|
CA3071597A1
|
|
Adjusted multi-biomarker disease activity score for inflammatory disease assessment
|
|
US2017314081A1
|
|
Methods of detecting cancer
|
|
US2018017580A1
|
|
Biomarkers for distinguishing mood disorders
|
|
CA3010240A1
|
|
Genes and gene signatures for diagnosis and treatment of melanoma
|
|
CA3005119A1
|
|
Signatures for predicting cancer immune therapy response
|
|
WO2016160484A1
|
|
Novel biomarkers for psychiatric disorders
|
|
WO2016094391A1
|
|
Methods and materials for predicting response to niraparib
|
|
AU2015358343A1
|
|
Biomarkers for distinguishing mood disorders
|
|
WO2016044142A1
|
|
Bladder cancer detection and monitoring
|
|
EP3180447A1
|
|
Methods and materials for assessing homologous recombination deficiency
|
|
EP3164508A1
|
|
Genes and gene signatures for diagnosis and treatment of melanoma
|
|
US2015344966A1
|
|
Hereditary Cancer Diagnostics
|
|
EP3143160A1
|
|
Gene signatures for cancer prognosis
|
|
CA2945175A1
|
|
Cancer prognosis signatures
|
|
US2015232947A1
|
|
Cancer biomarkers
|
|
EP3102697A1
|
|
Method for predicting the response to an anti-her2 containing therapy and/or chemotherapy in patients with breast cancer
|
|
US2015167100A1
|
|
Hereditary Cancer Genes
|
|
WO2015085095A1
|
|
Gene signatures for renal cancer prognosis
|
